Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANUS Trial
2024-515387-31-00Phase 2Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human mesenchymal stem cells in systemic sclerosis (SSc) and digital ulcer (DU) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Treatment toxicity at 12 weeks after MSC administration. Planned start Oct 2024; status: authorised.
02
Drugs
human mesenchymal stem cells
03
Conditions
systemic sclerosis (SSc)digital ulcer (DU)
Beyond the preview
Go deeper on 2024-515387-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515387-31-00.